Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients.

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac P ...

Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine , 2011; 110827230022006 DOI: 10.1056/NEJMoa1107039 Cite This Page : ...

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of ...

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).

Although apixaban caused much lower rates of major bleeding in frail patients when compared to Coumadin (eg, 40.7 such events per 1,000 person-years for dabigatran and 83.4 such events per 1,000 ...

Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine , 2011; 110827230022006 DOI: 10.1056/NEJMoa1107039 Cite This Page : ...

A 2012 study using indirect comparisons indicated that apixaban had a lower risk of major hemorrhage compared with other DOACs. And a 2018 analysis based on claims data showed that apixaban carried ...

DURHAM, NC — Projected lifetime treatment with the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) appears to be cost-effective vs warfarin for patients with atrial ...

The use of apixaban (Eliquis; Bristol-Myers Squibb) over rivaroxaban (Xarelto; Bayer/Janssen) in patients with atrial fibrillation (AF) and valvular heart disease is associated with better clinical ...

Results of a study comparing apixaban with low-molecular-weight heparin as a treatment to prevent recurrent blood clots in patients with cancer may assuage some of the concern about the bleeding ...